Predict your next investment

Corporation
HEALTHCARE | Biotechnology
denalitherapeutics.com

See what CB Insights has to offer

Founded Year

2015

Stage

IPO | IPO

Total Raised

$347M

Date of IPO

12/8/2017

Market Cap

7.71B

Stock Price

46.41

About Denali Therapeutics

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, ALS and others.

Denali Therapeutics Headquarter Location

161 Oyster Point Blvd

South San Francisco, California, 94080,

United States

Latest Denali Therapeutics News

Denali makes ALS play, hustling Sanofi-partnered drug into phase 2 and sharing early data on internal program

Oct 7, 2021

Denali’s internal and Sanofi-partnered amyotrophic lateral sclerosis programs tackle the disease from different angles. (Getty Images) Denali Therapeutics has set out its play for the amyotrophic lateral sclerosis (ALS) market, revealing early-phase data on one asset and plans to move a Sanofi-partnered program into phase 2 early in 2022. The new data come from a phase 1 trial that gave eIF2B activator DNL343 to 95 healthy volunteers. Denali emerged from the study with evidence DNL343 is generally well tolerated, gets to the central nervous system and has a pharmacokinetic profile that supports once-daily dosing. The study also saw changes in integrated stress response biomarkers, suggesting DNL343 engages with its target and acts on a pathway implicated in ALS. Denali saw enough positive signs in the early data to start a phase 1b study, which recently set out to enroll 30 ALS patients and randomize them to receive one of two doses of DNL343 or placebo. While the trial is primarily looking at the adverse event profile of DNL343, it will also start the process of answering outstanding questions about how patients respond to the molecule. “Primary pushback from investors is: hard to know what we have until there is more clinical data, biology around ALS is extremely challenging, preclinical models are not well predictive,” analysts at Jefferies wrote in a note to investors. The analysts expect Denali to eventually land a big partnership to fund the program.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Denali Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Denali Therapeutics in 1 CB Insights research brief, most recently on Jan 17, 2019.

Expert Collections containing Denali Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Denali Therapeutics is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

B

Biopharmaceuticals

14,139 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Denali Therapeutics Patents

Denali Therapeutics has filed 47 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Prodrugs
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/15/2021

9/21/2021

G protein coupled receptors, Clusters of differentiation, Immune system, Transcription factors, Monoclonal antibodies

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/15/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/21/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

G protein coupled receptors, Clusters of differentiation, Immune system, Transcription factors, Monoclonal antibodies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Denali Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Denali Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.